Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression

American Journal of Transplantation

Volumn 9, Issue 10, 2009, Pages 2331-2337

  Trappe, R ^a   Hinrichs, C ^a   Appel, U ^a   Babel, N ^a   Reinke, P ^a   Neumayer, H H ^a   Budde, K ^a   Dreyling, M ^b   Duhrsen U ^c   Kliem, V ^d   Schuttrumpf S ^e   Hauser, I A ^f   Mergenthaler, H G ^g   Schlattmann, P ^h   Anagnostopoulos, I ^f   Doerken, B ^a   Riess, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Nephrological Center   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g Department of Hematology and Oncology   (Germany)

^h Department of Biometrics and Clinical Epidemiology ^*

Author keywords

Chemotherapy; Immunosuppressive withdrawal; Kidney graft function; Kidney transplantation; Post transplant lymphoproliferative disorder (PTLD); Rituximab

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; RISK FACTORS; VINCRISTINE;

EID: 70349219929     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02772.x     Document Type: Article

References (25)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969 1 : 106 112.
2. Dodd GD 3rd., Greenler DP, Confer SR. Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiol Clin North Am 1992 30 : 597 610.
3. Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999 213 : 73 78.
4. Dotti G, Fiocchi R, Motta T et al. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 2002 74 : 1095 1102.
5. Bakker NA, van Imhoff GW, Verschuuren EA et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005 19 : 327 334.
6. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997 14 : 8 14.
7. Leblond V, Dhedin N, Mamzer Bruneel MF et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001 19 : 772 778.
8. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984 1 : 583 587.
9. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001 71 : 1076 1088.
10. Swinnen LJ, LeBlanc M, Grogan TM et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008 86 : 215 222.
11. Oertel SH, Verschuuren E, Reinke P et al. Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). Am J Transplant 2005 5 : 2901 2906.
12. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase II study. Blood 2006 107 : 3053 3057.
13. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007 92 : 1489 1494.
14. Choquet S, Oertel S, LeBlond V et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007 86 : 599 607.
15. Mamzer-Bruneel MF, Lome C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000 18 : 3622 3632.
16. Norin S, Kimby E, Ericzon BG et al. Posttransplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol 2004 21 : 273 284.
17. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 6 : 569 576.
18. Fohrer C, Caillard S, Koumarianou A et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006 134 : 602 612.
19. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007 92 : 273 274.
20. Trappe R, Choquet S, Oertel S et al. Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy? Blood 2007 110 : 390.
21. Oertel SH, Papp-Vary M, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003 123 : 830 835.
22. Wolfinger R, Tobias R, Sall J. Computing Gaussian likelihoods and their derivatives for general linear mixed models. SIAM J Sci Comput 1994 15 : 16.
23. Rehbinder B, Wullstein C, Bechstein WO et al. Epstein-barr virus-associated posttransplant lymphoproliferative disorder of donor origin after simultaneous pancreas-kidney transplantation limited to pancreas allograft: A case report. Am J Transplant 2006 6 : 2506 2511.
24. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: Emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983 12 : 359 372.
25. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008 127 : 280 285.